 Seattle Times |
Seattle Genetics's Experimental Drug Shrinks Hodgkin's Tumors, Study Shows
Bloomberg Seattle Genetics Inc. and Takeda Pharmaceutical Co.'s experimental drug wiped out tumors in one- third of patients with hard-to-treat Hodgkin's lymphoma and reduced the cancer by half in another 40 percent, … Seattle Genetics team may win clearance for anti-cancer drug Seattle Genetics to submit lymphoma drug to FDA Clinical Advances in Hodgkin Lymphoma |
View full post on Health – Google News
